154 related articles for article (PubMed ID: 29219612)
21. Avelumab expanded access program in metastatic Merkel cell carcinoma: Efficacy and safety findings from patients in Europe and the Middle East.
Ascierto PA; Orlova K; Grignani G; Dudzisz-Śledź M; Fenig E; Chiarion Sileni V; Fazio N; Samimi M; Mortier L; Gebhardt C; Kramkimel N; Steven N; Bechter O; Arance A; Benincasa E; Kostkova L; Costa N; Lorigan P
Int J Cancer; 2021 Dec; 149(11):1926-1934. PubMed ID: 34310716
[TBL] [Abstract][Full Text] [Related]
22. A cost-utility analysis of avelumab for metastatic Merkel cell carcinoma in Taiwan.
Chang WC; Lin AY; Hsu JC; Wu CE; Goh C; Chou P; Kuo K; Chang A; Palencia R
Cancer Rep (Hoboken); 2021 Dec; 4(6):e1399. PubMed ID: 33934577
[TBL] [Abstract][Full Text] [Related]
23. Avelumab: A Novel Anti-PD-L1 Agent in the Treatment of Merkel Cell Carcinoma and Urothelial Cell Carcinoma.
Teets A; Pham L; Tran EL; Hochmuth L; Deshmukh R
Crit Rev Immunol; 2018; 38(3):159-206. PubMed ID: 30004857
[TBL] [Abstract][Full Text] [Related]
24. PD-L1 blockade with avelumab: A new paradigm for treating Merkel cell carcinoma.
Barkdull S; Brownell I
Cancer Biol Ther; 2017 Dec; 18(12):937-939. PubMed ID: 29172995
[TBL] [Abstract][Full Text] [Related]
25. Avelumab for the treatment of metastatic Merkel cell carcinoma.
Cordes LM; Gulley JL
Drugs Today (Barc); 2017 Jul; 53(7):377-383. PubMed ID: 28837181
[TBL] [Abstract][Full Text] [Related]
26. Patient-reported outcomes and inflammatory biomarkers in patients with locally advanced/metastatic urothelial carcinoma treated with durvalumab in phase 1/2 dose-escalation study 1108.
O'Donnell PH; Arkenau HT; Sridhar SS; Ong M; Drakaki A; Spira AI; Zhang J; Gordon MS; Degboe AN; Gupta AK; Mukhopadhyay P; Huang W; Abdullah SE; Angra N; Roskos LK; Guo X; Friedlander T
Cancer; 2020 Jan; 126(2):432-443. PubMed ID: 31581306
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of avelumab treatment in patients with metastatic Merkel cell carcinoma: experience from a global expanded access program.
Walker JW; Lebbé C; Grignani G; Nathan P; Dirix L; Fenig E; Ascierto PA; Sandhu S; Munhoz R; Benincasa E; Flaskett S; Reed J; Engelsberg A; Hariharan S; Kasturi V
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32269140
[TBL] [Abstract][Full Text] [Related]
28. Survival Analysis in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab.
Lanitis T; Proskorovsky I; Ambavane A; Hunger M; Zheng Y; Bharmal M; Phatak H
Adv Ther; 2019 Sep; 36(9):2327-2341. PubMed ID: 31350728
[TBL] [Abstract][Full Text] [Related]
29. Complete response with neoadjuvant avelumab in Merkel cell carcinoma - A case report.
Abdallah N; Nagasaka M; Chowdhury T; Raval K; Hotaling J; Sukari A
Oral Oncol; 2019 Dec; 99():104350. PubMed ID: 31277904
[TBL] [Abstract][Full Text] [Related]
30. Merkel cell carcinoma in Latin America: a contribution from an expanded access program for avelumab to address issues from experts' recommendations.
Munhoz RR; Cayol F; Corrales L; Gerson R; Tilli M; Barreto EO; Sánchez Castillo JO; Schmerling RA; Cinat G
Cancer Immunol Immunother; 2021 Apr; 70(4):1031-1036. PubMed ID: 33104838
[TBL] [Abstract][Full Text] [Related]
31. Living with Merkel Cell Carcinoma (MCC): Development of a Conceptual Model of MCC Based on Patient Experiences.
Kaufman HL; Dias Barbosa C; Guillemin I; Lambert J; Mahnke L; Bharmal M
Patient; 2018 Aug; 11(4):439-449. PubMed ID: 29512061
[TBL] [Abstract][Full Text] [Related]
32. Diffuse lichen planus-like keratoses and clinical pseudo-progression associated with avelumab treatment for Merkel cell carcinoma, a case report.
Cardis MA; Jiang H; Strauss J; Gulley JL; Brownell I
BMC Cancer; 2019 Jun; 19(1):539. PubMed ID: 31164102
[TBL] [Abstract][Full Text] [Related]
33. How to address the challenges of evaluating treatment benefits-risks in rare diseases? A convergent mixed methods approach applied within a Merkel cell carcinoma phase 2 clinical trial.
Bharmal M; Guillemin I; Marrel A; Arnould B; Lambert J; Hennessy M; Fofana F
Orphanet J Rare Dis; 2018 Jun; 13(1):95. PubMed ID: 29914528
[TBL] [Abstract][Full Text] [Related]
34. [Merkel cell carcinoma in chronic lymphocytic leukemia : Successful treatment with PD-L 1 inhibition, avelumab and chlorambucil].
Dücker P; Hüning S; Rohde S; Lorenzen J; Nashan D
Hautarzt; 2020 Jul; 71(7):553-556. PubMed ID: 32394077
[TBL] [Abstract][Full Text] [Related]
35. Appearance of New Cutaneous Superficial Basal Cell Carcinomas during Successful Nivolumab Treatment of Refractory Metastatic Disease: Implications for Immunotherapy in Early Versus Late Disease.
Cohen PR; Kato S; Goodman AM; Ikeda S; Kurzrock R
Int J Mol Sci; 2017 Jul; 18(8):. PubMed ID: 28788102
[TBL] [Abstract][Full Text] [Related]
36. Avelumab in the Treatment of Advanced Merkel Cell Carcinoma: A Systematic Review.
Sharma AN; Shah KS; Sharma AA; Yu SS
Dermatol Surg; 2024 May; 50(5):407-411. PubMed ID: 38349855
[TBL] [Abstract][Full Text] [Related]
37. Lethal thrombocytopenia in a patient treated with avelumab for metastatic Merkel cell carcinoma.
Kratzsch D; Simon JC; Pönitzsch I; Ziemer M
J Dtsch Dermatol Ges; 2019 Jan; 17(1):73-75. PubMed ID: 30549433
[No Abstract] [Full Text] [Related]
38. Avelumab treatment in Italian patients with metastatic Merkel cell carcinoma: experience from an expanded access program.
Grignani G; Chiarion Sileni V; Pinto C; Depenni R; Fazio N; Galli L; Giuffrida D; Carnaghi C; Ciliberto D; Corsi DC; Queirolo P; Benincasa E; Venturini F; Fazzi G; Costa N; Ascierto PA
J Transl Med; 2021 Feb; 19(1):70. PubMed ID: 33588870
[TBL] [Abstract][Full Text] [Related]
39. Avelumab for the treatment of locally advanced or metastatic Merkel cell carcinoma-A multicenter real-world experience in Israel.
Averbuch I; Stoff R; Miodovnik M; Fennig S; Bar-Sela G; Yakobson A; Daliot J; Asher N; Fenig E
Cancer Med; 2023 Jun; 12(11):12065-12070. PubMed ID: 37012213
[TBL] [Abstract][Full Text] [Related]
40. Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial.
Cella D; Grünwald V; Nathan P; Doan J; Dastani H; Taylor F; Bennett B; DeRosa M; Berry S; Broglio K; Berghorn E; Motzer RJ
Lancet Oncol; 2016 Jul; 17(7):994-1003. PubMed ID: 27283863
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
